{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Grade+III+Neuroendocrine+Carcinoma", "query": { "condition": "Grade III Neuroendocrine Carcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 33, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Grade+III+Neuroendocrine+Carcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T13:45:56.127Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05039801", "title": "IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Endometrial Carcinoma", "Advanced Head and Neck Squamous Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Ovarian Clear Cell Adenocarcinoma", "Chondrosarcoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Recurrent Ovarian High Grade Serous Adenocarcinoma", "Refractory Endometrial Carcinoma", "Refractory Head and Neck Squamous Cell Carcinoma", "Refractory Melanoma", "Refractory Ovarian Clear Cell Adenocarcinoma", "Refractory Ovarian High Grade Serous Adenocarcinoma", "Stage III Ovarian Cancer AJCC v8", "Stage III Uterine Corpus Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Uterine Corpus Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Uterine Corpus Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Uterine Corpus Cancer AJCC v8", "Stage IIIC1 Uterine Corpus Cancer AJCC v8", "Stage IIIC2 Uterine Corpus Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Uterine Corpus Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Uterine Corpus Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Glutaminase-1 Inhibitor IACS-6274", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2021-09-30", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-06-25T13:45:56.127Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05039801" }, { "nct_id": "NCT00004922", "title": "Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma of Unknown Primary", "Neuroendocrine Carcinoma", "Neuroendocrine Carcinoma of the Skin" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-06", "completion_date": "2002-06", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-06-25T13:45:56.127Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004922" }, { "nct_id": "NCT03896958", "title": "The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer, All Types", "Cancer of Liver", "Cancer of Stomach", "Cancer of Head and Neck", "Cancer of Rectum", "Cancer of Kidney", "Cancer of Esophagus", "Cancer of Colon", "Cancer Skin", "Cancer of Cervix", "Cancer, Metastatic", "Cancer of Larynx", "Cancer of Neck", "Cancer of Lung", "Cancer of Brain and Nervous System", "Cancer of Vulva, Disseminated", "Cancer of Pancreas", "Sarcoma", "GIST", "Small-cell Lung Cancer", "Adenocarcinoma Lung", "Cancer of Prostate", "Cancer, Advanced", "Adrenal Cancer", "Testicular Cancer", "Uterine Cancer", "Bronchoalveolar Cell Lung Cancer", "Cancer Unknown Primary", "Glioblastoma Multiforme", "Oligodendroglioma", "Breast Cancer", "Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Cholangiocarcinoma", "Squamous Cell Carcinoma", "Transitional Cell Carcinoma", "Cancer, Other", "Cancer, Anal", "Melanoma", "Cancer, Bile Duct", "Cancer, Bladder", "Cancer Cords Vocal", "Cancers Cell Neuroendocrine", "Cancer Differentiated Poorly", "Cancer, Anaplastic Thyroid" ], "interventions": [], "intervention_types": [], "sponsor": "SpeciCare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "99 Years", "sex": "ALL", "summary": "1 Month to 99 Years" }, "enrollment_count": 1000, "start_date": "2019-03-21", "completion_date": "2024-03-12", "has_results": false, "last_update_posted_date": "2020-12-04", "last_synced_at": "2026-06-25T13:45:56.127Z", "location_count": 1, "location_summary": "Gainesville, Georgia", "locations": [ { "city": "Gainesville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03896958" }, { "nct_id": "NCT00049296", "title": "Thalidomide and Docetaxel in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2002-07", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2010-06-11", "last_synced_at": "2026-06-25T13:45:56.127Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00049296" }, { "nct_id": "NCT04452292", "title": "Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Large-Cell Neuroendocrine Carcinoma" ], "interventions": [ { "name": "Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma", "type": "OTHER" }, { "name": "Treatment for Small Cell Lung Cancer", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Charles Kunos", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2021-09-14", "completion_date": "2023-03-14", "has_results": true, "last_update_posted_date": "2023-05-17", "last_synced_at": "2026-06-25T13:45:56.127Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04452292" }, { "nct_id": "NCT04069299", "title": "Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neuroendocrine Carcinoma" ], "interventions": [ { "name": "68Ga-DOTATATE", "type": "DRUG" }, { "name": "Positron Emission Tomography (PET) Scan", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2019-09-25", "completion_date": "2025-06-02", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-06-25T13:45:56.127Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04069299" }, { "nct_id": "NCT05058651", "title": "Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced Extrapulmonary Neuroendocrine Carcinoma", "Metastatic Extrapulmonary Neuroendocrine Carcinoma", "Recurrent Extrapulmonary Neuroendocrine Carcinoma", "Unresectable Extrapulmonary Neuroendocrine Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Patient Observation", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 189, "start_date": "2022-06-28", "completion_date": "2028-10-01", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-06-25T13:45:56.127Z", "location_count": 250, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Anaheim, California + 190 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Auburn", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05058651" }, { "nct_id": "NCT06889493", "title": "SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroendocrine Carcinoma", "Neuroendocrine Tumors" ], "interventions": [ { "name": "Seneca Valley Virus-001 (SVV-001)", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Peter Hosein, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2025-05-19", "completion_date": "2030-06-01", "has_results": false, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-06-25T13:45:56.127Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06889493" }, { "nct_id": "NCT00161187", "title": "Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 37, "start_date": "2001-05", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2015-11-06", "last_synced_at": "2026-06-25T13:45:56.127Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00161187" }, { "nct_id": "NCT00049023", "title": "Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Gastrointestinal Carcinoid Tumor", "Islet Cell Tumor", "Neuroblastoma", "Pheochromocytoma", "Sarcoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "90Y-DOTA-tyr3-OCTREOTIDE", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "O'Dorisio, M S", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "2 Years to 25 Years" }, "enrollment_count": 27, "start_date": "2002-01", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2016-06-21", "last_synced_at": "2026-06-25T13:45:56.127Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00049023" } ] }